A Phase 2 interventional study of vorinostat in Advanced Cancer, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-05-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the safety and tolerability of continuing vorinostat (MK-0683) dosing in cancer patients previously enrolled in one of five base studies (MK-0683-001, MK-0683-006, MK-0683-008, MK-0683-012, or MK-0683-013) who have shown benefit from receiving this drug.
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: vorinostat
All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
Also known as: MK-0683
Percent of Participants With a Serious Drug-related Adverse Event (AE)
A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose. A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug.
Time frame: From the first dose of study drug until the patient experiences disease progression, withdraws consent, or develops unacceptable toxicity (from Day 1 up to 4 years and 9 months)
| Milestone | Base Protocol 001 | Base Protocol 006 | Base Protocol 008 | Base Protocol 012 | Base Protocol 013 |
|---|---|---|---|---|---|
| Started | 13 | 1 | 7 | 4 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 1 | 7 | 4 | 2 |
| Withdrew: Adverse event | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Not specified or withdrew consent | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Disease progression | 8 | 1 | 6 | 4 | 2 |
A serious adverse event (SAE) was any AE occurring at any dose that resulted in death, was life-threatening, resulted in a persistent or significant disability/incapacity, resulted in or prolonged an existing inpatient hospitalization, was a congenital anomaly/birth defect, was a cancer, or was an overdose. A drug-related SAE was one that was thought to be possibly, probably, or definitely related to the study drug.
| percent of participants | Base Protocol 001 | Base Protocol 006 | Base Protocol 008 | Base Protocol 012 | Base Protocol 013 |
|---|---|---|---|---|---|
| Percent of Participants With a Serious Drug-related Adverse Event (AE) | 7.7 | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | — | 4/13 (30.8%) | 6/13 (46.2%) |
| Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID]) | — | 1/1 (100%) | 0/1 (0%) |
| Base Protocol 008 (Vorinostat 400 mg Once Daily [QD]) | — | 1/7 (14.3%) | 2/7 (28.6%) |
| Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21) | — | 0/1 (0%) | 0/1 (0%) |
| Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7) | — | 1/1 (100%) | 1/1 (100%) |
| Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21) | — | 0/1 (0%) | 0/1 (0%) |
| Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21) | — | 0/1 (0%) | 0/1 (0%) |
| Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21) | — | 0/1 (0%) | 1/1 (100%) |
| Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7) | — | 0/1 (0%) | 1/1 (100%) |
| Event | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID]) | Base Protocol 008 (Vorinostat 400 mg Once Daily [QD]) | Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21) | Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7) | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21) | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21) | Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21) | Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7) |
|---|---|---|---|---|---|---|---|---|---|
| Chest painGeneral disorders | 0/13 | 0/1 | 0/7 | 0/1 | 1/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| CholangitisHepatobiliary disorders | 0/13 | 1/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Ovarian cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/1 | 1/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Tongue neoplasm malignant stage unspecifiedNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/13 | 0/1 | 1/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| CholecystitisHepatobiliary disorders | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| PneumoniaInfections and infestations | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Blood creatine phosphokinase increasedInvestigations | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| RashSkin and subcutaneous tissue disorders | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Event | Base Protocol 001 (Vorinostat 400 mg Once Daily [QD]) | Base Protocol 006 (Vorinostat 200 mg Twice Daily [BID]) | Base Protocol 008 (Vorinostat 400 mg Once Daily [QD]) | Base Protocol 012 (Vorinostat 400 mg Once Daily [QD] 7/21) | Base Protocol 012 (Vorinostat 300 mg Twice Daily [BID] 3/7) | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 14/21) | Base Protocol 012 (Vorinostat 300 mg Once Daily [QD] 7/21) | Base Protocol 013 (Vorinostat 200 mg Twice Daily [BID] 14/21) | Base Protocol 013 (Vorinostat 300 mg Twice Daily [BID] 3/7) |
|---|---|---|---|---|---|---|---|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 3/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 1/1 | 0/1 |
| NauseaGastrointestinal disorders | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 1/1 |
| FatigueGeneral disorders | 0/13 | 0/1 | 0/7 | 0/1 | 1/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Lobar pneumoniaInfections and infestations | 0/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 1/1 | 0/1 |
| DiarrhoeaGastrointestinal disorders | 2/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Abdominal pain lowerGastrointestinal disorders | 0/13 | 0/1 | 1/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| AnorexiaMetabolism and nutrition disorders | 0/13 | 0/1 | 1/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| ConstipationGastrointestinal disorders | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Blood creatine phosphokinase increasedInvestigations | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Blood lactate dehydrogenase increasedInvestigations | 1/13 | 0/1 | 0/7 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 | 0/1 |
| Age, Customized(Participants) | Base Protocol 001 | Base Protocol 006 | Base Protocol 008 | Base Protocol 012 | Base Protocol 013 | Total |
|---|---|---|---|---|---|---|
| Number | 13 | 1 | 7 | 4 | 2 | 27 |
| Sex: Female, Male(Participants) | Base Protocol 001 | Base Protocol 006 | Base Protocol 008 | Base Protocol 012 | Base Protocol 013 | Total |
|---|---|---|---|---|---|---|
| Female | 8 | 0 | 4 | 1 | 2 | 15 |
| Male | 5 | 1 | 3 | 3 | 0 | 12 |
No study locations are listed for this record.
The record gives a start of Aug 2005, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat